Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...
Cytokinetics recently announced that MYQORZO (aficamten), a cardiac myosin inhibitor for adults with symptomatic obstructive hypertrophic cardiomyopathy, is now commercially available in the U.S. via ...
Most physicians said the positives of clozapine's REMS outweighed its negatives. Most also said that mandatory blood testing was necessary, but it created a burden and medication delays. In 2024, an ...
A joint FDA advisory committee on Tuesday overwhelming voted to eliminate the risk evaluation and mitigation strategy (REMS) program designed around the risk for severe neutropenia associated with ...
The FDA still recommends prescribers monitor patients’ ANC levels according to the prescribing information. The Food and Drug Administration (FDA) has removed the risk evaluation and mitigation ...
US regulators removed a special safety program intended to monitor for certain heart risks with vandetanib (Caprelsa), a drug first approved in 2011 to treat medullary thyroid cancer in patients whose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results